ArticleJournal of controlled release : official journal of the Controlled Release Society2025
Engineering vaginal film platform for mucoadhesion and sustained drug release for HIV-1 prevention.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Impact of the Vaginal Microbiome and Microbial Metabolites on HIV Transmission at the Female Reproductive Tract Epithelial Barrier.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
User adherence contributes to the effectiveness of topical pre-exposure prophylactic products designed to protect against human immunodeficiency virus type 1 (HIV-1) infection. Long-acting approaches that do not require daily or coitally-dependent use could potentially improve user adherence. This study aims to develop a long-acting vaginal film to deliver an integrase inhibitor, MK-2048, for prevention of HIV-1 infection. To this end, a film platform fabricated with thiolated chitosan and poly(lactide-co-Ɛ-caprolactone) (PLACL) was designed to achieve long residence time and sustained drug release profile, respectively. A series of PLACLs were synthesized with different lactic acid (LA) to caprolactone (CL) ratios and were chemically and thermally characterized. Films containing thiolated chitosan and PLACL copolymers were manufactured using solvent-casting and characterized for their physicochemical properties. The in vitro release of MK-2048 formulated in thiomer PLACL films was tested. The lead film composed of thiomers and PLACL 80 showed comparable elasticity with the marketed VCF® film (vaginal contraceptive film) and slower drug release rate compared to other compositions. The tissue mucoadhesion and permeability of MK-2048 were significantly improved by incorporation of thiolated chitosan in the film matrix. Importantly, the film showed no evidence of toxicity in excised human ectocervical tissue and demonstrated comparable anti-HIV activity as free MK-2048. The lead film evaluated in pigtail macaques showed drug concentrations above the IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.